Print

Purpose

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults ≥18 years of age - Clinical diagnosis of T1D - GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week - Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study - Willing and able to provide informed consent

Exclusion Criteria

  • No exclusion criteria other than those not meeting inclusion criteria above

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Prospective

Recruiting Locations

Harvard Medical School
Boston, Massachusetts 02115
Contact:
Grace Ordonez
617-732-4245
gordonez@bwh.harvard.edu

More Details

Status
Recruiting
Sponsor
Indiana University

Study Contact

Kanchan Bhasin, MBBS
(317)-278-2752
kanbhas@iu.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.